Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers’ Compensation System View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04

AUTHORS

Leslie Wilson, Fatema Turkistani, Dang M. Tran, Wei Huang, Tracy Kuo Lin

ABSTRACT

BACKGROUND: Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. The objectives of this study are (1) to explore any trends in physician-dispensed drug prices; (2) to compare the proportion of drugs with and without a price and to determine the financial implications of repricing CAWCS physician-dispensed drugs with five alternative pricing benchmarks; and (3) to offer recommendations for the pricing benchmark to maximize pricing coverage and to remain budget neutral. METHODS: We evaluated physician-dispensed drugs at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported. We matched each claim line in the CAWCS to the corresponding unit price of an alternative price benchmark including average wholesale price, wholesale acquisition cost, direct prices, national average drug acquisition cost, and Federal Upper Limit. RESULTS: Average wholesale price provided prices for 99.9% of physician-dispensed drug claims, while Medi-Cal, the current primary physician-dispensed drug benchmark provided prices for a lower percentage (92.7%) of claims. The CAWCS prices were equivalent to 49% of the average wholesale price, 95.5% of Medi-Cal, 126.7% of the wholesale acquisition cost, 266% of the Federal Upper Limit, 64.4% of direct prices, and 197% of national average drug acquisition cost-estimated prices. CONCLUSIONS: The CAWCS current Medi-Cal pricing for physician-dispensed drugs is better than all alternatives in terms of price availability, transparency, and budget neutrality, but pricing availability may decrease over time as Medi-Cal moves to managed care. National average drug acquisition cost is the next best alternative, but it requires combinations of pricing benchmarks to maximize its price availability. More... »

PAGES

231-242

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40258-018-0442-2

DOI

http://dx.doi.org/10.1007/s40258-018-0442-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110227293

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30484140


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA", 
            "Department of Medicine, Health Policy and Economics, University of California San Francisco, 3333 California Street, Suite 420, Box 0613, 94143, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilson", 
        "givenName": "Leslie", 
        "id": "sg:person.01144105425.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144105425.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taibah University", 
          "id": "https://www.grid.ac/institutes/grid.412892.4", 
          "name": [
            "Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA", 
            "Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Al-Madinah, Saudi Arabia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Turkistani", 
        "givenName": "Fatema", 
        "id": "sg:person.016263136625.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016263136625.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tran", 
        "givenName": "Dang M.", 
        "id": "sg:person.011402123157.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011402123157.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Wei", 
        "id": "sg:person.013304552462.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013304552462.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "London School of Economics and Political Science", 
          "id": "https://www.grid.ac/institutes/grid.13063.37", 
          "name": [
            "Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA", 
            "Department of Social Policy, London School of Economics and Political Science, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lin", 
        "givenName": "Tracy Kuo", 
        "id": "sg:person.016436545671.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016436545671.66"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/b978-0-12-375678-7.01209-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021604567"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jom.0000000000000145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032216934"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jom.0000000000000145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032216934"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajim.20208", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033552309"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajim.20208", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033552309"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18553/jmcp.2010.16.7.492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068661077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075076435", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2139/ssrn.1676213", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1102292667"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0197449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104235724"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04", 
    "datePublishedReg": "2019-04-01", 
    "description": "BACKGROUND: Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. The objectives of this study are (1) to explore any trends in physician-dispensed drug prices; (2) to compare the proportion of drugs with and without a price and to determine the financial implications of repricing CAWCS physician-dispensed drugs with five alternative pricing benchmarks; and (3) to offer recommendations for the pricing benchmark to maximize pricing coverage and to remain budget neutral.\nMETHODS: We evaluated physician-dispensed drugs at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported. We matched each claim line in the CAWCS to the corresponding unit price of an alternative price benchmark including average wholesale price, wholesale acquisition cost, direct prices, national average drug acquisition cost, and Federal Upper Limit.\nRESULTS: Average wholesale price provided prices for 99.9% of physician-dispensed drug claims, while Medi-Cal, the current primary physician-dispensed drug benchmark provided prices for a lower percentage (92.7%) of claims. The CAWCS prices were equivalent to 49% of the average wholesale price, 95.5% of Medi-Cal, 126.7% of the wholesale acquisition cost, 266% of the Federal Upper Limit, 64.4% of direct prices, and 197% of national average drug acquisition cost-estimated prices.\nCONCLUSIONS: The CAWCS current Medi-Cal pricing for physician-dispensed drugs is better than all alternatives in terms of price availability, transparency, and budget neutrality, but pricing availability may decrease over time as Medi-Cal moves to managed care. National average drug acquisition cost is the next best alternative, but it requires combinations of pricing benchmarks to maximize its price availability.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40258-018-0442-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1031175", 
        "issn": [
          "1175-5652", 
          "1179-1896"
        ], 
        "name": "Applied Health Economics and Health Policy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "name": "Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers\u2019 Compensation System", 
    "pagination": "231-242", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f2833d2fda785c8aacc85a37c91e53782ae3c9007c917deef85e22a37a615dc2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30484140"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101150314"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40258-018-0442-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110227293"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40258-018-0442-2", 
      "https://app.dimensions.ai/details/publication/pub.1110227293"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78950_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40258-018-0442-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40258-018-0442-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40258-018-0442-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40258-018-0442-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40258-018-0442-2'


 

This table displays all metadata directly associated to this object as RDF triples.

126 TRIPLES      21 PREDICATES      36 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40258-018-0442-2 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N1d94a6ab1ea04f9887706b0cfc7e73df
4 schema:citation https://app.dimensions.ai/details/publication/pub.1075076435
5 https://doi.org/10.1002/ajim.20208
6 https://doi.org/10.1016/b978-0-12-375678-7.01209-8
7 https://doi.org/10.1097/jom.0000000000000145
8 https://doi.org/10.1371/journal.pone.0197449
9 https://doi.org/10.18553/jmcp.2010.16.7.492
10 https://doi.org/10.2139/ssrn.1676213
11 schema:datePublished 2019-04
12 schema:datePublishedReg 2019-04-01
13 schema:description BACKGROUND: Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. The objectives of this study are (1) to explore any trends in physician-dispensed drug prices; (2) to compare the proportion of drugs with and without a price and to determine the financial implications of repricing CAWCS physician-dispensed drugs with five alternative pricing benchmarks; and (3) to offer recommendations for the pricing benchmark to maximize pricing coverage and to remain budget neutral. METHODS: We evaluated physician-dispensed drugs at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported. We matched each claim line in the CAWCS to the corresponding unit price of an alternative price benchmark including average wholesale price, wholesale acquisition cost, direct prices, national average drug acquisition cost, and Federal Upper Limit. RESULTS: Average wholesale price provided prices for 99.9% of physician-dispensed drug claims, while Medi-Cal, the current primary physician-dispensed drug benchmark provided prices for a lower percentage (92.7%) of claims. The CAWCS prices were equivalent to 49% of the average wholesale price, 95.5% of Medi-Cal, 126.7% of the wholesale acquisition cost, 266% of the Federal Upper Limit, 64.4% of direct prices, and 197% of national average drug acquisition cost-estimated prices. CONCLUSIONS: The CAWCS current Medi-Cal pricing for physician-dispensed drugs is better than all alternatives in terms of price availability, transparency, and budget neutrality, but pricing availability may decrease over time as Medi-Cal moves to managed care. National average drug acquisition cost is the next best alternative, but it requires combinations of pricing benchmarks to maximize its price availability.
14 schema:genre research_article
15 schema:inLanguage en
16 schema:isAccessibleForFree false
17 schema:isPartOf N709a48fb4c7b4d67870253337b644fe6
18 Nac8e3566af184423a94726512e95d132
19 sg:journal.1031175
20 schema:name Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers’ Compensation System
21 schema:pagination 231-242
22 schema:productId N3c06a1ea99394c4dac2d3d19d2b1368e
23 N79ddd9645eb84148be4a3a8e51f7e3a0
24 Nb8031edbb85645b89a1b0155e1bc99a7
25 Nc1d7ec7d0fea468d8b93d05bbeb93272
26 Nea7e100c3ead4a12a99cc0765992c1c5
27 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110227293
28 https://doi.org/10.1007/s40258-018-0442-2
29 schema:sdDatePublished 2019-04-11T13:19
30 schema:sdLicense https://scigraph.springernature.com/explorer/license/
31 schema:sdPublisher N59ff98b42e474f17bece461d4051c8ff
32 schema:url https://link.springer.com/10.1007%2Fs40258-018-0442-2
33 sgo:license sg:explorer/license/
34 sgo:sdDataset articles
35 rdf:type schema:ScholarlyArticle
36 N04e768c4b83346d58307c2fd3b8afe63 rdf:first sg:person.013304552462.02
37 rdf:rest Ndb1d8d375299438cac01720322be4901
38 N0f0bb8d4aed048e6a0d61d7153aa2fc6 rdf:first sg:person.011402123157.55
39 rdf:rest N04e768c4b83346d58307c2fd3b8afe63
40 N1d94a6ab1ea04f9887706b0cfc7e73df rdf:first sg:person.01144105425.42
41 rdf:rest N3ec41e42283a4ffdb36ea862b14e97dd
42 N3c06a1ea99394c4dac2d3d19d2b1368e schema:name pubmed_id
43 schema:value 30484140
44 rdf:type schema:PropertyValue
45 N3ec41e42283a4ffdb36ea862b14e97dd rdf:first sg:person.016263136625.17
46 rdf:rest N0f0bb8d4aed048e6a0d61d7153aa2fc6
47 N59ff98b42e474f17bece461d4051c8ff schema:name Springer Nature - SN SciGraph project
48 rdf:type schema:Organization
49 N709a48fb4c7b4d67870253337b644fe6 schema:issueNumber 2
50 rdf:type schema:PublicationIssue
51 N79ddd9645eb84148be4a3a8e51f7e3a0 schema:name dimensions_id
52 schema:value pub.1110227293
53 rdf:type schema:PropertyValue
54 Nac8e3566af184423a94726512e95d132 schema:volumeNumber 17
55 rdf:type schema:PublicationVolume
56 Nb8031edbb85645b89a1b0155e1bc99a7 schema:name nlm_unique_id
57 schema:value 101150314
58 rdf:type schema:PropertyValue
59 Nc1d7ec7d0fea468d8b93d05bbeb93272 schema:name doi
60 schema:value 10.1007/s40258-018-0442-2
61 rdf:type schema:PropertyValue
62 Ndb1d8d375299438cac01720322be4901 rdf:first sg:person.016436545671.66
63 rdf:rest rdf:nil
64 Nea7e100c3ead4a12a99cc0765992c1c5 schema:name readcube_id
65 schema:value f2833d2fda785c8aacc85a37c91e53782ae3c9007c917deef85e22a37a615dc2
66 rdf:type schema:PropertyValue
67 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
68 schema:name Economics
69 rdf:type schema:DefinedTerm
70 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
71 schema:name Applied Economics
72 rdf:type schema:DefinedTerm
73 sg:journal.1031175 schema:issn 1175-5652
74 1179-1896
75 schema:name Applied Health Economics and Health Policy
76 rdf:type schema:Periodical
77 sg:person.011402123157.55 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
78 schema:familyName Tran
79 schema:givenName Dang M.
80 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011402123157.55
81 rdf:type schema:Person
82 sg:person.01144105425.42 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
83 schema:familyName Wilson
84 schema:givenName Leslie
85 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144105425.42
86 rdf:type schema:Person
87 sg:person.013304552462.02 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
88 schema:familyName Huang
89 schema:givenName Wei
90 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013304552462.02
91 rdf:type schema:Person
92 sg:person.016263136625.17 schema:affiliation https://www.grid.ac/institutes/grid.412892.4
93 schema:familyName Turkistani
94 schema:givenName Fatema
95 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016263136625.17
96 rdf:type schema:Person
97 sg:person.016436545671.66 schema:affiliation https://www.grid.ac/institutes/grid.13063.37
98 schema:familyName Lin
99 schema:givenName Tracy Kuo
100 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016436545671.66
101 rdf:type schema:Person
102 https://app.dimensions.ai/details/publication/pub.1075076435 schema:CreativeWork
103 https://doi.org/10.1002/ajim.20208 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033552309
104 rdf:type schema:CreativeWork
105 https://doi.org/10.1016/b978-0-12-375678-7.01209-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021604567
106 rdf:type schema:CreativeWork
107 https://doi.org/10.1097/jom.0000000000000145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032216934
108 rdf:type schema:CreativeWork
109 https://doi.org/10.1371/journal.pone.0197449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104235724
110 rdf:type schema:CreativeWork
111 https://doi.org/10.18553/jmcp.2010.16.7.492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068661077
112 rdf:type schema:CreativeWork
113 https://doi.org/10.2139/ssrn.1676213 schema:sameAs https://app.dimensions.ai/details/publication/pub.1102292667
114 rdf:type schema:CreativeWork
115 https://www.grid.ac/institutes/grid.13063.37 schema:alternateName London School of Economics and Political Science
116 schema:name Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA
117 Department of Social Policy, London School of Economics and Political Science, London, UK
118 rdf:type schema:Organization
119 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
120 schema:name Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA
121 Department of Medicine, Health Policy and Economics, University of California San Francisco, 3333 California Street, Suite 420, Box 0613, 94143, San Francisco, CA, USA
122 rdf:type schema:Organization
123 https://www.grid.ac/institutes/grid.412892.4 schema:alternateName Taibah University
124 schema:name Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA
125 Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Al-Madinah, Saudi Arabia
126 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...